|
|
|
2 April 2003
Melbourne, Australia. 2 April 2003: Orphan Australia Pty Ltd had submitted
an application for registration of Ferriprox® (deferiprone) to the Therapeutic
Goods Administration (TGA) in Australia.
This application was approved on 2 April, 2003 for the treatment of iron-overload
in patients with thalassaemia major who are unable to take desferrioxamine
therapy; or, in whom desferrioxamine therapy has proven ineffective.
The next step in our programme is to submit an application for price reimbursement
to the Pharmaceutical Benefits Advisory Committee (PBAC).
Dr Rob Lindeman, Senior Staff Specialist Haematologist at the Prince of Wales
Hospital, Randwick NSW, said, “The availability of deferiprone in Australia
represents a major step forward for our patients with thalassaemia major.
Without chelation therapy, these patients almost inevitably succumb early
to the complications of iron overload, which is an inevitable consequence
of lifelong blood transfusions. While desferrioxamine has an excellent track
record in allowing patients to avoid iron overload, some patients are unable
to tolerate the drug. Deferiprone offers this group the possibility of effective
iron chelation, and is also of use in patients in whom desferrioxamine fails
to achieve negative iron balance, and is therefore ineffective.”
Ferriprox is licensed to Orphan Australia by Apotex Inc. Apotex and its affiliated
companies is the largest Canadian-owned pharmaceutical Group with over 4,000
employees and an R& D commitment of over $1 billion for the next 10 years
to develop both generic and innovative medicines.
Orphan Australia is a privately owned pharmaceutical company based in Melbourne,
providing niche products to Australia and the local region. Orphan Australia
specialises in the development, marketing and distribution of products typically
used by specialists to treat serious and/or life threatening disorders.
Ferriprox® is a registered trademark of Apotex Inc., used under licence
by Orphan Australia Pty Ltd.
For Further Information Contact:
Orphan Australia
Gennaro D’Alessandro
Manager – New Products
gennaro@orphan.com.au
Telephone: (03) 9769 5744
Dr Rob Lindeman
Senior Staff Specialists Haematologist
Prince of Wales Hospital
Randwick NSW
Telephone: (02) 9382 2222
Telephone : 61 3 9769 5744 ----- Facsimile : 61 3 9769 5944 ----- Email : info@orphan.com.au
Company | Product | Professionals | Related Links | Contact | Home